CD22 Antibody ( FITC )

CD22 Antibody Datasheet

CD22 Antibody Product Information

• Immunogen: Recombinant Human CD22 protein (Catalog#11958-H08H)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 05
• Ig Type: Mouse IgG1
• Concentration: 10 μl/Test, 0.1 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD22 (rh CD22; Catalog#11958-H08H; P20273-1; Met 1-Arg 687) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

CD22 Antibody Usage Guide

• Specificity: Human CD22
• Flow Cytometry:
  

  Profile of anti-CD22 reactivity on Daudi cells analyzed by flow cytometry. Cells should be Fc-blocked by treatment with 20 μg of human IgG/106 cells for 1 hour at 4 ℃ prior to staining, washed, then stained with FITC Mouse anti-CD22.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃- 8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

CD22 Antibody Background

CD22 is a molecule belonging to the immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family. It is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The CD22 cell-surface adhesion molecule is capable of modulating B lymphocyte antigen receptor (BCR)-mediated signals, as well as the generation of BCR-independent signals. CD22 is an inhibitory coreceptor of the B-cell receptor (BCR), and plays a critical role in establishing signalling thresholds for B-cell activation. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. Interaction of CD22 to ligands in trans can regulate both B-cell migration as well as the BCR signaling threshold. However, a more complex role for CD22 has recently emerged, including a central role in a novel regulatory loop controlling the CD19/CD21-Src-family protein tyrosine kinase (PTK) amplification pathway that regulates basal signaling thresholds and intensifies Src-family kinase activation after BCR ligation. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1. Thus, the CD19/CD22 loop may be a potential therapeutic target in autoimmune disease for modulating B cell signaling.

References

1. Sato S. et al., 1998, Semin Immunol. 10 (4): 287-97.
2. Walker JA. et al., 2008, Immunology. 123 (3): 314-25.
3. Nitschke L. 2009, Immunol Rev. 230 (1): 128-43.
4. Tedder TF. et al., 2005, Adv Immunol. 88: 1-50.
5. Fujimoto M. et al., 2007, J Dermatol Sci. 46 (1): 1-9.